RBC Capital lowered the firm’s price target on Karyopharm (KPTI) to $33 from $43 and keeps an Outperform rating on the shares after its Q1 results. There were a few incrementally unfavorable updates this quarter, as slowing enrollment for the SENTRY phase 3 Myelofibrosis – MF – study is pushing data out to December/January – beyond the company’s cash runway, the analyst tells investors in a research note. RBC adds however that Phase 2 data in heavily-pretreated MF continues to support seli’s potential MF activity, and the firm sees both MF and EC offer very realistically-achievable shots on goal in indications that could meaningfully inflect revenue.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KPTI:
- Karyopharm price target lowered to $42 from $54 at Baird
- Karyopharm price target adjusted to $10 from $5 at Barclays
- Karyopharm Therapeutics Reports Q1 2025 Earnings and Clinical Progress
- Karyopharm reports Q1 EPS ($2.77), consensus ($3.09)
- Karyopharm sees 2025 revenue $140M-$155M, consensus $149.62M
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue